NCT04652570View on ClinicalTrials.gov

Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

November 21, 2023

Study Completion Date

August 15, 2024

Conditions
Membranous Nephropathy
Interventions
DRUG

VB119

Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.

Trial Locations (4)

12209

Clinical Research Site, Albany

18017

Clinical Research Site, Bethlehem

75208

Clinical Research Site, Dallas

91324

Clinical Reserach Site, Los Angeles

Sponsors

Lead Sponsor

Tenet Medicines
All Listed Sponsors
lead

Tenet Medicines

INDUSTRY